Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

MUHC researchers develop new model to identify ovarian cancer genes

16.08.2006
Researchers from the MUHC have developed a new model to identify ovarian cancer genes. This innovative research, published in the journal Oncogene, is a significant step towards improving treatment for this devastating disease that kills more than two-thirds of people diagnosed.

"Our findings now provide tangible targets for effective drug development. Up to now, there has been little in the way of treatment options for this disease, which is one of the most lethal of cancers," says Dr. Patricia Tonin, MUHC cancer geneticist and associate professor of Medicine and Human Genetics at McGill University. "This model not only allows us to identify the specific human chromosome 3 genes responsible for affecting tumour growth, but also has great potential to pinpoint genes in the entire human genome that would be most affected by this process."

"Ovarian cancer studies have shown the alteration of hundreds of genes. The challenge is to identify those genes that affect ovarian cancer from those which don't. Our model can be used to do just that, so that we can focus our attention on those genes most likely to affect tumour growth."

Tonin, along with Dr. Mario Chevrette, MUHC molecular biologist and assistant professor of Surgery at McGill University, and colleagues at the Institut du cancer de Montréal and Centre-Hospitalier de l'Universite de Montreal (CHUM), used a novel DNA transfer technique to move DNA from a non-tumour cell line to a human ovarian cancer cell line. The newly created cell line was then assessed for its ability to form tumours. Ovarian cancer cells that took up the non-tumour DNA lost their ability to produce these tumours. Subsequent genetic analyses revealed that a group of genes located on chromosome 3 genes were responsible for converting the cancer cell line into a non-tumour cell line. In addition, specific genes elsewhere in the human genome were affected in this process, some of which were novel and others never before studied in ovarian cancer.

This research was funded in part by the Canadian Institutes of Health Research (CIHR). "Too many women die of ovarian cancer each year," says Dr. Philip Branton, Scientific Director of the CIHR Institute of Cancer Research. "This is ground-breaking work. The more we can understand about what causes tumours to develop and what stimulates their growth, the greater are our chances of targeted treatments for women diagnosed with ovarian cancer."

Ovarian cancer starts in the cells of the ovaries-the egg producing reproductive organs on either side of the womb. There are three main types of ovarian cancer: epithelial, germ and stromal. This year alone 2,300 new cases of ovarian cancer will be diagnosed and approximately 1,600 women will die from the disease.

The Research Institute of the McGill University Health Centre (RI MUHC) is a world-renowned biomedical and health care hospital research centre. Located in Montreal, Quebec, the institute is the research arm of the MUHC, a university health centre affiliated with the Faculty of Medicine at McGill University. The institute supports over 500 researchers, nearly 1,000 graduate and postdoctoral students, and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge.

The McGill University Health Centre (MUHC) is a comprehensive academic health institution with an international reputation for excellence in clinical programs, research and teaching. The MUHC is a merger of five teaching hospitals affiliated with the Faculty of Medicine at McGill University-the Montreal Children's, Montreal General, Royal Victoria, and Montreal Neurological Hospitals, as well as the Montreal Chest Institute. Building on the tradition of medical leadership of the founding hospitals, the goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care field, and to contribute to the development of new knowledge.

The Canadian Institutes of Health Research (CIHR) is the Government of Canada's agency for health research. CIHR's mission is to create new scientific knowledge and to catalyze its translation into improved health, more effective health services and products, and a strengthened Canadian health care system. Composed of 13 Institutes, CIHR provides leadership and support to over 10,000 health researchers and trainees across Canada.

Ian Popple | MUHC
Further information:
http://www.cihr-irsc.gc.ca
http://www.nature.com/onc/journal/vaop/ncurrent/abs/1209821a.html
http://www.muhc.ca/research

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>